Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
暂无分享,去创建一个
H. Concin | C. Seger | A. Griesmacher | N. Concin | L. Wildt | S. Ziehr | B. Seeber | V. Mattle | Andreas Gschlieβer | C. Moser
[1] C. Seger,et al. An ultra-sensitive online SPE-LC-MS/MS method for the quantification of levonorgestrel released from intrauterine devices , 2011, Analytical and bioanalytical chemistry.
[2] H. Concin,et al. Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective , 2009, Current opinion in obstetrics & gynecology.
[3] L. Bahamondes,et al. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. , 2009, Contraception.
[4] P. Thonneau,et al. Contraceptive efficacy of intrauterine devices. , 2008, American journal of obstetrics and gynecology.
[5] C. Lauritzen,et al. Praktische Hormontherapie in der Gynäkologie , 2007 .
[6] J. Griffin,et al. The textbook of pharmaceutical medicine , 2005 .
[7] R. Reid,et al. Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. , 2005, Contraception.
[8] I. Rauramo,et al. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. , 2001, Fertility and sterility.
[9] R. Luoto,et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation‐wide study of 17,360 users , 2000, BJOG : an international journal of obstetrics and gynaecology.
[10] V. Odlind,et al. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. , 1999, Acta obstetricia et gynecologica Scandinavica.
[11] A. Kauppila,et al. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. , 1999, Fertility and sterility.
[12] D. Mishell,et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. , 1997, Contraception.
[13] D. Mishell,et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. , 1991, Contraception.
[14] J. Toivonen,et al. Protective Effect of Intrauterine Release of Levonorgestrel on Pelvic Infection: Three Years' Comparative Experience of Levonorgestrel- and Copper-Releasing Intrauterine Devices , 1991, Obstetrics and gynecology.
[15] B. Xiao,et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. , 1990, Contraception.
[16] A. Breckenridge,et al. Clinical Pharmacokinetics of Oral Contraceptive Steroids , 1983, Clinical pharmacokinetics.
[17] T. Luukkainen,et al. TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD , 1982, Clinical endocrinology.
[18] V. Odlind,et al. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. , 1994, Contraception.
[19] I. Sivin,et al. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). , 1994, Fertility and sterility.
[20] J. Toivonen. The levonorgestrel-releasing intrauterine device. , 1994, Advances in contraceptive delivery systems : CDS.